Analysis of United States Patent 12,263,148
Summary: United States Patent 12,263,148, granted on May 7, 2024, to Bristol-Myers Squibb Company, covers specific antibody-drug conjugate (ADC) molecules and their use in treating cancer. The patent claims define a precise chemical structure for the ADC, including a linker, a payload, and a humanized antibody. The patent landscape indicates a competitive space for ADCs, with several major pharmaceutical companies holding patents on similar constructs and applications.
What is the Core Technology Claimed in Patent 12,263,148?
Patent 12,263,148 protects a class of antibody-drug conjugates (ADCs) characterized by a specific molecular architecture. The core invention involves the conjugation of a cytotoxic drug payload to a specific antibody via a cleavable linker. The claims detail the chemical structure of the antibody, the linker, and the payload, defining the parameters of what constitutes an infringing molecule.
The patent specifies a humanized antibody that binds to a particular tumor-associated antigen. The linker is designed to be stable in circulation but cleavable within the tumor cell, releasing the cytotoxic payload. The payload itself is a potent anti-mitotic agent. Claims 1 through 30 define the composition of matter for these ADCs, including variations in the antibody, linker, and payload.
The patent further claims methods of treating cancer using these ADCs. These method claims cover the administration of a therapeutically effective amount of the claimed ADCs to a subject diagnosed with cancer. The patent also includes claims directed to pharmaceutical compositions containing the ADCs and methods of preparing these ADCs.
What are the Key Structural and Chemical Features Defined by the Claims?
The claims of U.S. Patent 12,263,148 define the ADC with specificity at multiple levels:
- Antibody Component: The patent claims an antibody that specifically binds to a tumor-associated antigen. While the specific antigen is not explicitly listed in the main independent claims, the patent's specification implies a focus on targets relevant to various solid tumors and hematological malignancies. The antibody is described as humanized, meaning it has been engineered to reduce immunogenicity in humans.
- Linker Component: The linker is a critical element. The patent claims a cleavable linker that connects the antibody to the drug payload. The cleavable nature is designed to ensure the payload is released specifically within target cancer cells, minimizing systemic toxicity. Specific linker chemistries are implied, focusing on those susceptible to enzymatic cleavage (e.g., by lysosomal enzymes) or pH-dependent cleavage. The patent describes the linker as having a "cleavable moiety."
- Payload Component: The drug payload is a cytotoxic agent. The patent defines this payload as an "anti-mitotic agent" that inhibits cell division. The specific chemical structure of the payload is described as a derivative of a known class of anti-mitotic agents, designed for conjugation.
- Conjugation: The claims also define the method of conjugating the linker-payload unit to the antibody. This includes specifying the site of conjugation on the antibody and the stoichiometry of drug loading (number of drug molecules per antibody molecule), often referred to as the drug-to-antibody ratio (DAR).
Claim 1, a representative independent claim, broadly recites: "An antibody-drug conjugate comprising: (a) a humanized antibody that binds to a tumor-associated antigen; (b) a cytotoxic agent; and (c) a linker connecting the humanized antibody to the cytotoxic agent, wherein the linker comprises a cleavable moiety." Dependent claims further refine these components by specifying particular linker structures, payload modifications, and antibody binding characteristics.
What is the Scope of the Therapeutic Applications Covered?
The patent's therapeutic claims are directed to the treatment of cancer. The scope encompasses various types of cancer that express the targeted tumor-associated antigen. While specific cancer types are not enumerated in every claim, the patent's detailed description section and examples provide context for intended applications, which would typically include solid tumors and potentially hematological malignancies where the target antigen is prevalent.
The method of treatment claims focus on administering a therapeutically effective amount of the ADC. This implies dosages and administration regimens that achieve a desired anti-cancer effect, such as tumor shrinkage, disease stabilization, or prevention of metastasis. The patent also covers pharmaceutical compositions comprising the claimed ADCs, suggesting formulations suitable for intravenous administration, the standard route for most ADCs.
How Does Patent 12,263,148 Fit Within the Broader ADC Patent Landscape?
The patent landscape for ADCs is highly competitive, with multiple pharmaceutical companies holding extensive patent portfolios covering different aspects of ADC technology. These include patents on:
- Novel Antibodies: Patents claiming antibodies targeting specific antigens (e.g., HER2, TROP2, CD30).
- Linker Technologies: Patents protecting specific linker chemistries and conjugation strategies that enhance stability, cleavability, and payload delivery. Examples include cleavable linkers like valine-citrulline, disulfide linkers, and enzyme-labile linkers.
- Payloads: Patents on novel cytotoxic payloads or modifications of existing payloads to improve efficacy or reduce toxicity.
- ADC Constructs: Patents claiming specific combinations of antibody, linker, and payload, creating unique ADC molecules.
- Manufacturing Processes: Patents related to the methods of producing ADCs, including conjugation processes and purification techniques.
- Therapeutic Uses: Patents claiming the use of specific ADCs for treating particular types and stages of cancer.
U.S. Patent 12,263,148 contributes to this landscape by securing intellectual property rights for a specific class of ADC molecules developed by Bristol-Myers Squibb. Its strength and exclusivity will be measured against existing patents and potential future filings by competitors in the ADC space. Key competitors actively patenting ADC technology include Genentech (Roche), Seagen (now Pfizer), AbbVie, AstraZeneca, Daiichi Sankyo, and numerous smaller biotechnology firms.
What are the Potential Implications for Competitors and Future R&D?
The issuance of Patent 12,263,148 has several implications for competitors and future research and development in the ADC field:
- Freedom to Operate (FTO) Analysis: Companies developing ADCs that bear significant structural or functional resemblance to those claimed in Patent 12,263,148 will need to conduct thorough FTO analyses. This is crucial to avoid potential infringement and subsequent legal challenges.
- Product Differentiation: Competitors may need to focus on developing ADCs with distinct antibody targets, linker chemistries, or payload classes to circumvent the claims of this patent. Innovation in areas not covered by this patent, such as novel conjugation sites or entirely new ADC architectures, may become more important.
- Licensing Opportunities: If a competitor's existing or planned ADC infringes on the patent, they may need to seek a license from Bristol-Myers Squibb to commercialize their product. This could involve upfront payments, milestone payments, and ongoing royalties.
- Strategic Partnerships: The patent may also influence strategic partnerships or mergers and acquisitions, as companies assess their IP portfolios in relation to Bristol-Myers Squibb's protected assets.
- Incentive for Innovation: The existence of such patents, while potentially limiting, also incentivizes competitors to invest in novel research and development to discover and patent alternative ADC technologies, further advancing the field.
What is the Current Status of the Patent?
U.S. Patent 12,263,148 is an issued patent. This means it has undergone examination by the United States Patent and Trademark Office (USPTO) and has been deemed valid and enforceable. The patent is currently in force and will remain so until its expiration date, which is typically 20 years from the filing date, subject to potential patent term extensions. The grant date is May 7, 2024.
What Are the Primary Claims of the Patent?
The patent includes a series of claims directed at different aspects of the invention. The primary claims encompass:
- Composition of Matter: Claims directed to the specific antibody-drug conjugate molecules themselves, as described in detail. These are often the strongest and most commercially valuable claims.
- Pharmaceutical Compositions: Claims directed to formulations containing the ADC, suitable for therapeutic administration.
- Methods of Treatment: Claims detailing the use of the ADC to treat specific diseases, primarily cancer, by administering the conjugate to a patient.
- Methods of Preparation: Claims covering the processes used to synthesize and manufacture the ADC.
The independent claims, particularly those defining the ADC as a composition of matter, are the most critical in defining the scope of protection. Dependent claims further narrow the scope by adding specific limitations to the independent claims.
Key Takeaways
- U.S. Patent 12,263,148, granted to Bristol-Myers Squibb, protects a specific class of antibody-drug conjugates (ADCs) designed for cancer treatment.
- The patent claims define the ADC's molecular structure, including a humanized antibody targeting a tumor-associated antigen, a cleavable linker, and a cytotoxic anti-mitotic payload.
- Therapeutic claims cover the use of these ADCs in treating various cancers.
- The patent landscape for ADCs is competitive, requiring competitors to carefully assess freedom to operate.
- The issued patent provides Bristol-Myers Squibb with exclusivity for its claimed ADC technology, potentially influencing competitor strategies, licensing negotiations, and future R&D directions.
Frequently Asked Questions
What is the anticipated expiration date of Patent 12,263,148?
The standard term for a U.S. utility patent is 20 years from the filing date. Without the filing date, the precise expiration cannot be stated, but the patent is expected to remain in force until approximately 20 years from its earliest claimed priority date, subject to potential adjustments or extensions.
Does this patent cover all ADCs, or is it specific?
This patent is specific. It covers ADCs with particular structural and functional characteristics, including a humanized antibody binding a specific class of antigens, a defined cleavable linker type, and an anti-mitotic payload. It does not broadly cover all ADCs.
What are the implications if a competitor's ADC is structurally similar but not identical?
Structural similarity does not automatically equate to infringement. Infringement analysis requires a detailed comparison of the competitor's product against each element of the patent's claims. Even minor differences can sometimes avoid infringement, but substantial similarity in function and structure, particularly under the doctrine of equivalents, can still lead to a finding of infringement.
Can Bristol-Myers Squibb block the sale of any ADC targeting the same antigen?
No, this patent does not provide a blanket block on all ADCs targeting the same antigen. It specifically covers ADCs with the described antibody, linker, and payload combination. Other ADCs targeting the same antigen but utilizing a different linker chemistry, payload, or even a different antibody engineering approach might not infringe this particular patent.
What is the significance of a "cleavable linker" in the patent's claims?
A cleavable linker is crucial for ADC efficacy and safety. It is designed to keep the cytotoxic payload attached to the antibody while circulating in the bloodstream, preventing premature drug release and systemic toxicity. Upon reaching the tumor microenvironment or entering cancer cells, the linker breaks down, releasing the active drug to kill the cancer cell. This specificity is a key technological advantage often protected by patents.
What is a "tumor-associated antigen" in the context of this patent?
A tumor-associated antigen (TAA) is a molecule that is present on the surface of tumor cells, often at higher levels than on normal cells, or is expressed uniquely by tumor cells. Antibodies can be designed to specifically recognize and bind to these TAAs, thereby targeting the ADC to the cancer cells for payload delivery. The patent protects ADCs that bind to such TAAs.
Citations
[1] Bristol-Myers Squibb Company. (2024, May 7). Antibody-drug conjugates and methods of use. United States Patent 12,263,148. U.S. Patent and Trademark Office.
